Glaxo Sends Paxil Warning Letter to Your Doctor

Almost a year after the FDA mandated stronger warning labels on 10 selective serotonin reuptake inhibitors (SSRIs) -- the most commonly prescribed class of antidepressants -- GlaxoSmithKline recently begun sending cautionary letters to doctors about an increased risk of suicide attempts among young adults (ages 18-30) connected to the popular drug Paxil and Paxil CR (generic name paroxetine).

Interesting, the company sent letters voluntarily, based on an analysis of some 9,000 patients (ages 18-64) who took Paxil during clinical trials versus nearly 6,000 who took a placebo. Among those taking Paxil for depression, the 18-30 age group was more affected by far than any other in relation to attempted suicide (eight of the 11 incidents reported).

Despite the company warning, however, the FDA hasn't announced changes to existing SSRI guidelines. And, they're still urging patients not to stop taking their Paxil.

The two morals from this news:

New York Times May 12, 2006 Registration Required

ABC News May 12, 2006

Click Here and be the first to comment on this article
Post your comment